Skip to main content

Precipio HemeScreen

Precipio this week commercially launched HemeScreen, a test for mutations in hematologic cancers. The test measures for mutations in the CALR, JAK2, JAK2 exon 12, and MPL genes, which are critically important to developing the clinical roadmap for the patient, Precipio said. The company will offer the assay through its CLIA laboratory in New Haven, Connecticut, and will also offer a set of RUO reagents to other reference labs to perform the test in their CLIA laboratories.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.